• Share:

Publications 2011

Can't find the PDF you are looking for? Email Jessica Kohn for assistance.


Publications: 2011

Vultur A, Villanueva J, Herlyn M. Targeting BRAF in advanced melanoma: a first step towards manageable disease. Clin Cancer Res. 2011;17:1658-1663. Link to Article

Thurber AE, Douglas G, Sturm EC, Zabierowski SE, Smit DJ, Ramakrishnan SN, Hacker E, Leonard JH, Herlyn M, Sturm RA. Inverse expression of BRN2 and MITF transcription factors in melanoma spheres and tumor xenografts regulate the NOTCH pathway. Oncogene. 2011;30:3036-3048. Link to Article

Magnitsky S, Roesch A, Herlyn M, Glickson JD. In vivo and ex vivo MR imaging of slowly cycling melanoma cells. Magn Reson Med. 2011;66:1362-1372. Link to Article

Basu D, Montone KT, Wang L-P, Gimotty PA, Hammond R, Diehl JA, Rustgi AK, Lee JT, Rasanen K, Weinstein GS, Herlyn M. Detecting and targeting mesenchymal-like subpopulations within squamous cell carcinomas. Cell Cycle. 2011;10:2008-2016. Link to Article

Li L, Fukunaga-Kalabis M, Herlyn M. The three-dimensional human skin reconstruct model: a tool to study normal skin and melanoma progression. J Vis Exp. 2011;54:e2937. Link to Article

Zabierowski SE, Fukunaga-Kalabis M, Li L, Herlyn M. Dermis-derived stem cells: a source of epidermal melanocytes and melanoma? Pigment Cell Melanoma Res. 2011;24:422-429. Link to Article

Fukunaga-Kalabis M, Roesch A, Herlyn M. From cancer stem cells to tumor maintenance cells. J Invest Dermatol. 2011;131:1600-1604. Link to Article

Zhang G, Herlyn M. Tumor microenvironment for melanoma cells. In: Bosserhoff A, ed. Melanoma Development. New York: Springer; 2011:297-308.

Herlyn M, Villanueva J. Sorting through the many opportunities for melanoma therapy. Pigm Cell Melanoma Res. 2011;24:975-7. Link to Article

Somasundaram R, Villanueva J, Herlyn M. Will engineered T cells expressing CD20 scFv eradicate melanoma? Mol Ther. 2011;19:638-640. Link to Article

Zabierowski SE, Baubet V, Himes B, Li L, Fukunaga-Kalabis M, Patel S, McDaid R, Guerra M, Gimotty P, Dahmane N, Herlyn M. Direct reprogramming of melanocytes to neural crest stem-like cells by one defined factor. Stem Cells. 2011;1752-62. Link to Article

Ohashi S, Natsuizaka M, Naganuma S, Kagawa S, Kimura S, Itoh H, Kalman RA, Nakagawa M, Darling DS, Basu D, Gimotty PA, Klein-Szanto AJ, Diehl JA, Herlyn M, Nakagawa H. A NOTCH3-mediated squamous cell differentiation program limits expansion of EMT competent cells that express the ZEB transcription factors. Cancer Res. 2011;71:6636-6847. Link to Article

Flach EH, Rebecca VW, Herlyn M, Smalley KSM, Anderson ARA. Fibroblasts contribute to melanoma tumor growth and drug resistance. Molecular Pharm. 2011;8:2039-2049. Link to Article

Blanck S, Cruchter T, Vultur A, Riedel R, Harms K, Herlyn M, Meggers E. Organometallic pyridylnaphthalimide complexes as protein kinase inhibitors. Organometallics. 2011;30:4598-4606. Link to Article

Villanueva J, Vultur A, Herlyn M. Resistance to BRAF inhibitors: unraveling mechanisms and future treatment options. Cancer Res. 2011;71:7137-7140. Link to Article

Bogenrieder T, Herlyn M. The molecular pathology of cutaneous melanoma. Cancer Biomark. 2011;9:267-286. Link to Article

Feng Y, Barile E, De SK, Stebbins JL, Cortez A, Aza-Blanc P, Villanueva J, Herlyn M, Krajewski S, Melecchia M, Ronai ZA, Chiang GG. Effective inhibition of melanoma by BI-69A11 is mediated by dual targeting of the AKT and NF-kB pathways. Pigm Cell Mel Res. 2011;24:703-713. Link to Article